Eltrombopag (Promacta, Revolade)

Indications

  • Thrombocytopenia (see Thrombocytopenia, [[Thrombocytopenia]]): FDA-approved in 2008
    • Refractory Aplastic Anemia (see Aplastic Anemia, [[Aplastic Anemia]]): FDA-approved for this indication in 2/14
    • Thrombocytopenia Associated with Cirrhosis Due to Hepatitis C (see End-Stage Liver Disease, [[End-Stage Liver Disease]])
    • Immune Thrombocytopenic Purpura (ITP) (see Immune Thrombocytopenic Purpura, [[Immune Thrombocytopenic Purpura]])

Pharmacology

  • Small Molecule Agonist of Thrombopoetin Receptor (cMpl): increases platelet production

Administration

  • xxxx

Adverse Effects

Cardiovascular Adverse Effects

  • Orthostatic Hypotension (see Hypotension, [[Hypotension]])

Dermatologic Adverse Effects

  • Alopecia (see Alopecia, [[Alopecia]])
  • Pruritus (see Pruritus, [[Pruritus]])
  • Rash

Hematologic Adverse Effects

  • Bone Marrow Reticulin Deposition
  • Hemorrhage
  • Increased Risk of Hematologic Malignancy
  • Thrombosis/Thromboembolism (see Hypercoagulable States, [[Hypercoagulable States]])
  • Worsening Thrombocytopenia After Eltrombopag Discontinuation

Gastrointestinal/Hepatic Adverse Effects

  • Abdominal Pain (see Abdominal Pain, [[Abdominal Pain]])
  • Diarrhea (see Diarrhea, [[Diarrhea]])
  • Hepatotoxicity/Hepatic Decompensation: when used in patients with hepatitis C
  • Nausea/Vomiting (see Nausea and Vomiting, [[Nausea and Vomiting]])

Neurologic Adverse Effects

Otolaryngologic Adverse Effects

  • Oropharyngeal Pain
  • Rhinorrhea
  • Upper Respiratory Infection
  • Xerostomia

Rheumatologic Adverse Effects

Other Adverse Effects

  • Cataracts (see Cataracts, [[Cataracts]])
  • Cough (see Cough, [[Cough]])
  • Fever (see Fever, [[Fever]])

References

  • xxxx